k - 31.ppt

48
SIMPATOMIMETIKA SIMPATOLITIK Jazanul Anwar_Hasanul Arifin Departemen Farmakologi & Terapeutik Fakultas Kedokteran USU 2009

Upload: selvie87

Post on 21-Jan-2016

40 views

Category:

Documents


0 download

DESCRIPTION

k-31

TRANSCRIPT

Page 1: K - 31.ppt

SIMPATOMIMETIKA

SIMPATOLITIK

Jazanul Anwar_Hasanul Arifin

Departemen Farmakologi & Terapeutik

Fakultas Kedokteran USU

2009

Page 2: K - 31.ppt

SIMPATOMIMETIKA

Page 3: K - 31.ppt

syaraf pasca ganglion

neurotransmiter

sintesa

penimbunan

penglepasan

perombakan

reseptor perangsangan

perangsangan

Simpatomimetika

perangsangan

Page 4: K - 31.ppt

TYROSINE _METYLDOPA_> NA ___ NA

2

2

1

1

3

Adrenalin

COMT MAO

Page 5: K - 31.ppt
Page 6: K - 31.ppt

Adrenergik dan

Penghambat Adrenergik

NE

NE

NE

D

D

DD

D

reseptor

Simpatomimetik yang bekerja

langsung

/NE

NE

NE

NE

NE

D

D

reseptor

NE

NENE

D

NED

D

reseptor

A

B

C

Simpatomimetik yang bekerja tidak

langsung

Simpatomimetik yang bekerja

campuran

D : obat simpatomimetik

E/NE

amfetamine

Page 7: K - 31.ppt

Simpatomimetika langsung

Simpatomimetika tak langsung

Page 8: K - 31.ppt

SIMPATOMIMETIKA (KIMIAWI)

Endogen: adrenalinnoradrenalindopamin

 Nonendogen: 1-adrenergik : phenylephrine, methoxamin

2-adrenergik : clonidine, oxymetazoline

-adrenergik : adrenalin

-adrenergik : isoprenaline

1-adrenergik : dobutamine

2-adrenergik : terbutaline, procaterol

Dopamin (D) : dopamin

D1 : fenoldopam

D2 : bromocriptin

CATECHOLAMINE

NONCATECHOLAMINE : amfetamin, metamfetamin

Page 9: K - 31.ppt

1 Agonists

Methoxamine

Penylpropranolamine

Phenylephrine

Mephentermine

Metaraminol

Mitodrine

Page 10: K - 31.ppt

1 Agonists Response utama & kegunaan klinik

Methoxamine: i.v. hipotensi

es paroxysmal takhikardi

Phenylephrine: | vasokonstriksi

nasal decongestant

Phenylpropranolamine: vasokonstriksi

nasaldecongestant

Mephentermine: direk & indirek, i.m.

Metaraminol

Mitodrine

Resistens vaskuler perifer naik

Page 11: K - 31.ppt

1 AgonistsKontraindikasi

• Hypertension

• Ischemic organ diseases

• Pembesaran Prostrat

• Pemberian bersama dg obat-obat jg menambah kadar NA– MAO inhibitors– sympathomimetika tak langsung

Page 12: K - 31.ppt

2 Agonists

Prototype

Clonidine

Brimonidine

Page 13: K - 31.ppt

2 Agonists Response utama & tempat kerja

• Response– Vasodilatasi

– Produksi cairan mata berkurang

• Tempat kerja– Peripheral

• Prejunctional: mengurangi penglepasan NA• Some postjunctional sites (eye, pancreas,

platelets)

– SSP: mengurangi sympathetic outflow

Page 14: K - 31.ppt

2 Agonists Kegunaan klinik

• Antihypertensives

• Menurunkan tekanan intraocular glaucoma sudut terbuka

Page 15: K - 31.ppt

2 AgonistsCara pemberian

• Oral

• Transdermal

• Topical (to eye)

Page 16: K - 31.ppt

2 AgonistsEfek samping

• Bradycardia

• SSP (50% of population)– sedasi – mulut kering

• Disfungsi Sexual

Page 17: K - 31.ppt

Agonists

Prototype – Dobutamine

Response utama - Kardiostimulasi• Kegunaan klinik

– Gagal jantung– Shock Cardiogenic

• Efek tak diinginkan– Arrythmias

Page 18: K - 31.ppt

2 Agonists

Prototypes

Albuterol

Salbutamol

Salmeterol

Ritodrine

Page 19: K - 31.ppt

2 Agonists Responses

• Bronchodilation– Albuterol

– Salbutamol

– Salmeterol

– Terbutalin

• Uterine dilation– Ritodrine

Page 20: K - 31.ppt

2 AgonistsClinical uses

• Bronchodilatasi– Asthma– COPD

• Tocolytic agents– Late term gestation

Page 21: K - 31.ppt

2 AgonistsEfek tak diinginkan

• Symptoms stimulasi 1 – Tachycardia

– Widening pulse pressure (systolic pressure rise)

• Symptoms of 2 stimulation– Widening pulse pressure (diastolic pressure drop)

– Drop in serum K+ (skeletal muscle uptake)

– Skeletal muscle tremor

Page 22: K - 31.ppt

2 AgonistsAdverse Effects (Con’t.)

• CNS– Anxiety

– Restlessness

– Apprehension

• Tolerance to bronchodilation– Without tolerance to adverse effect such as

tachycardia.

Page 23: K - 31.ppt

2 AgonistsContraindications

• Cardiac disease– Coronary artery disease– Arrhythmias

• Diabetes

• Hyperthyroidism

• Co-administration – MAO inhibitors– Indirect-acting sympathomimetics

Page 24: K - 31.ppt

Adrenergik Reseptor Pemakaian dalam klinik

Epinefrin (Adrenalin) 1, β1, β2 Anafilaktik syok, asma akut, henti jantung

Efedrin 1, β1, β2 Hipotensi, bronkospasme, kongesti hidung

NE 1, β1 Syok vasokonstriktor kuat

Pseudoefedrin 1, β1 Dekongestan

Fenilefrin 1 Dekongestan

Fenilpropanolamin (PPA) 1, β1 Dekongestan

Dopamin β1 Hipotensi

Isoproterenol β1, β2 Payah jantung kongestif aliran darah miokardium dan curah jantung

Metaproterenol Β1, β2 Bronkospasme, blok jantung akut

Albuterol β2 Bronkospasme

Terbutalin β2 Relaksasi uterus

Obat-obat adrenergik /simpatomimetik

Page 25: K - 31.ppt

SIMPATOLITIKA

Page 26: K - 31.ppt

syaraf pasca ganglion

neurotransmiter

sintesa

penimbunan

penglepasan

perombakan

reseptor perangsangan

penghambatan

perangsangan

penghambatan

Simpatomimetika Simpatolitika

perangsangan penghambatan

penghambatan

penghambatan

penghambatan

Page 27: K - 31.ppt

PENGHAMBAT SINTESA

Blokade penimbunan

BLOKADE PENGLEPASAN

BLOKADE RESEPTOR

Page 28: K - 31.ppt

NT inhibition

• On presynaptic ending– Drug affecting NT synthesis– Drug affecting NT storage– Drug affecting NT release

• On postsynaptic ending– Drug affecting parasympathetic receptors– Drug affecting sympathetic receptors

Page 29: K - 31.ppt

SIMPATOLITIKA

PRASINAPS

PASCASINAPS

PENGHAMBAT SINTESA

-METHYL DOPA

BLOKADE PENIMBUNAN

RESERPINE

PENGHAMBAT PENGLEPASAN NA

GUANETHIDINE

BLOKADE RESEPTOR

BLOKADE RESEPTOR

Page 30: K - 31.ppt

BLOKADE PENYIMPANAN NA

RESERPINE (RAUWOLFIA SERPENTINE)

KEGUNAAN KLINIK: HIPERTENSI

EFEK SAMPING: ssp- DEPRESI

SEDASI

PERIFERI NASAL CONGESTI

PENGHAMBAT PENGLEPASAN NA

GUANETHIDINE

Page 31: K - 31.ppt

Selectivity of AntagonistsSelective antagonists

•Nonselective (1/2) antagonists

•Selective 1 antagonists

•“Uroselective” 1A antagonists

Selective antagonists

Nonselective (2) antagonists

Selective 1 antagonists

Nonselective adrenergic ( antagonists

Page 32: K - 31.ppt

Nonselective Antagonists

Clinical Uses: Limited

Pheochromocytoma

Benign prostatic obstruction

(Phenoxybenzamine)

Autonomic hyperreflexia

Adverse Effects

Migraine headache

(Ergot alkaloids)

Cardiovascular

Tachycardia (reflex)Orthostatic hypotentionNasal congestion

Non cardiovascular

GI (Phentolamine)Impotence (Phenoxybenzamine)Potential mutagen (Phenoxybenzamine)

Page 33: K - 31.ppt

Selective 1 Antagonists

• Advantage over non-selective agents– lack 2 component

• less prejunctional control (less reflex tachycardia)

• less CNS component of action

• Uses – Hypertension

– Congestive heart failure

– Benign prostatic

hyperplasia• Prazosin (BID dosage)

• Doxazosin &Terazosin (QD dosage)

– Pheochromocytoma

Page 34: K - 31.ppt

Selective 1 Antagonists

• Adverse Effects– Orthostatic hypotension

• Usually becomes tolerated

• Give first dose at night

– Nasal congestion

Page 35: K - 31.ppt

“Uroselective” 1A Antagonist

• Tamsulosin– QD dosage

• Clinical Use– Benign Prostatic Hyperplasia

• Adverse Effects– Retrograde ejaculation– NOTE: Avoids orthostatic hypotension in

most

Page 36: K - 31.ppt

Selective 2 Antagonists

• Yohimbine

• Apparent Mechanism of Action– major mechanism of action appears to be

increasing sympathetic outflow from CNS

• Clinical Uses - (limited):– Impotency– Diabetic neuropathy pain– Orthostatic hypotension

Page 37: K - 31.ppt

Antagonists• In hypertensive (hyperkinetic heart-induced)

– Decrease blood pressure• In heart failure

– Decrease heart work & protect against arrythmias

• Asthma or other bronchospasm– cause bronchoconstriction

• Diabetes– mask symptoms of insulin-induced hypoglycemia

– augment insulin-induced hypoglycemia

Page 38: K - 31.ppt

Antagonists

• Prototype - Propranolol– Pure antagonist, no Intrinsic Sympathomimetic Activity(ISA) (i.e. not a

partial agonist)

– Nonselective to subtypes

– High lipid solubility - Enters gut & CNS

– High first pass metabolism - causing low bioavailability

– Has membrane-stabilizing activity• Quinidine-like effects, Na+ channel blockade, (local anesthetic)

Page 39: K - 31.ppt

Antagonists

• Nonselective– Propranolol

– Nadolol: long half-life

– Timolol: use in glaucoma

– Pindolol: ISA

• Selective1 – Metoprolol

– Atenolol: limited entry

– Esmolol: short half-life

– Acebutolol: ISA

–Bisoprolol

Page 40: K - 31.ppt

Uses of Antagonists

• Cardiovascular– Hypertension

– Angina

– Arrhythmias

– Myocardial infarction

– Heart failure

– CV Symptoms of• Hyperthyroidism

• Pheochromocytoma

• Aortic aneurysm

– Migraine headache

• Non-cardiovascular– Glaucoma

– Somatic symptoms of anxiety (e.g. stage fright)

– Fine muscle tremors

Page 41: K - 31.ppt

Nonselective Adrenergic Antagonists

• Labetalol: and 1 antagonist – Partial 2 agonist

• Carvedilol and 1 antagonist– Antioxidant– Anti-ischemic agent– Recent report supports it improves cardiac

performance > than metoprolol in chronic heart failure

Page 42: K - 31.ppt

Antagonists• Adverse Effects

– Cardiovascular• Induce CHF or bradycardial arrhythmia

• Sudden withdrawal - in anginal patients may cause sudden death (due to receptor supersensitivity)

– Bronchospasm

– CNS - sleep disturbance, depression

– Lacking recognition of hypoglycemia

Page 43: K - 31.ppt

Penghambat Adrenergik / Simpatolitik

Penghambat Adrenergik Reseptor Pemakaian dalam klinik

Tolazolin Hipertensi

Fentolamin Hipertensi

Prazosin Hipertensi

Propanolol β1, β2 Hipertensi, aritmia, angina pectoris, pasca infark miokardium

Nadolol β1, β2 Hipertensi, angina

Pindolol β1, β2 Hipertensi

Timolol β1, β2 Hipertensi, pasca infark miokardium

Metoprolol β1 Hipertensi, angina, pasca infark miokardium

Atenolol β1 Hipertensi, angina

Asebutolol β1 Hipertensi, aritmia ventrikel

Page 44: K - 31.ppt

Thank you

Page 45: K - 31.ppt

Benign prostatic hyperplasia (BHP)

• Incidence – 50% of age >60

90% of age >85• Definition: Nonmalignant enlargement of

prostate due to growth of – Epithelia/glandular (mechanical obstruction)

– Smooth muscle (dynamic obstruction - urethra)

• Symptoms: hesitancy, urgency, frequency, dysuria, nocturia, straining, dribbling, etc.

Page 46: K - 31.ppt

Antagonists

Mechanism & Sites of Actions

Cardiovascular - vascular smooth musclecontraction

Reversal adrenalinePrejunctional 2 negative feedback on NE release

Non-cardiovascular sites

Bladder

Page 47: K - 31.ppt

AntagonistsNonselective

Phentolamine (reversible, competitive)

Phenoxybenzamine (irreversible, noncompetitive)

Ergot alkaloids (dirty drugs with multiple sites of action)

Selective 1 antagonists Prazosin

“Uroselective” 1A antagonistsTamsulosin

Page 48: K - 31.ppt

Antagonists• Response in “normal” person during

stress– Short-term effect

• Block heart sympathetic response – rate and contraction - decrease CO – block of sympathetic control of rhythm & automaticity

• Increase TPR (block vascular 2 & increased reflex sympathetic tone)

– Long term effect• CO remains down• TPR returns to normal